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Abstract
Background: Multi-gene interactions likely play an important role in the development of complex phenotypes,
and relationships between interacting genes pose a challenging statistical problem in microarray analysis, since the
genes involved in these interactions may not exhibit marginal differential expression. As a result, it is necessary to
develop tools that can identify sets of interacting genes that discriminate phenotypes without requiring that the
classification boundary between phenotypes be convex.
Results: We describe an extension and application of a new unsupervised statistical learning technique, known as
the Partition Decoupling Method (PDM), to gene expression microarray data. This method may be used to classify
samples based on multi-gene expression patterns and to identify pathways associated with phenotype, without
relying upon the differential expression of individual genes. The PDM uses iterated spectral clustering and
scrubbing steps, revealing at each iteration progressively finer structure in the geometry of the data. Because
spectral clustering has the ability to discern clusters that are not linearly separable, it is able to articulate
relationships between samples that would be missed by distance- and tree-based classifiers. After projecting the
data onto the cluster centroids and computing the residuals ("scrubbing”), one can repeat the spectral clustering,
revealing clusters that were not discernible in the first layer. These iterations, each of which provide a partition of
the data that is decoupled from the others, are carried forward until the structure in the residuals is
indistinguishable from noise, preventing over-fitting. We describe the PDM in detail and apply it to three publicly
available cancer gene expression data sets. By applying the PDM on a pathway-by-pathway basis and identifying
those pathways that permit unsupervised clustering of samples that match known sample characteristics, we show
how the PDM may be used to find sets of mechanistically-related genes that may play a role in disease. An R
package to carry out the PDM is available for download.
Conclusions: We show that the PDM is a useful tool for the analysis of gene expression data from complex
diseases, where phenotypes are not linearly separable and multi-gene effects are likely to play a role. Our results
demonstrate that the PDM is able to distinguish cell types and treatments with higher accuracy than is obtained
through other approaches, and that the Pathway-PDM application is a valuable technique for identifying disease-
associated pathways.
Background
Since their first use nearly fifteen years ago [1], microar-
ray gene expression profiling experiments have become
a ubiquitous tool in the study of disease. The vast num-
ber of gene transcripts assayed by modern microarrays
(10
5-10
6) has driven forward our understanding of biolo-
gical processes tremendously, elucidating the genes and
regulatory mechanisms that drive specific phenotypes.
However, the high-dimensional data produced in these
experiments–often comprising many more variables
than samples and subject to noise–also presents analyti-
cal challenges.
The analysis of gene expression data can be broadly
grouped into two categories: the identification of differ-
entially expressed genes (or gene-sets) between two or
more known conditions, and the unsupervised identifi-
cation (clustering) of samples or genes that exhibit simi-
lar profiles across the data set. In the former case, each
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any medium, provided the original work is properly cited.gene is tested individually for association with the phe-
notype of interest, adjusting at the end for the vast
number of genes probed. Pre-identified gene sets, such
as those fulfilling a common biological function, may
then be tested for an overabundance of differentially
expressed genes (e.g., using gene set enrichment analysis
[2]); this approach aids biological interpretability and
improves the reproducibility of findings between micro-
array studies. In clustering, the hypothesis that function-
ally related genes and/or phenotypically similar samples
will display correlated gene expression patterns moti-
vates the search for groups of genes or samples with
similar expression patterns. The most commonly used
algorithms are hierarchical clustering [3], k-means clus-
tering [4,5] and Self Organizing Maps [6]; a brief over-
view may be found in [7]. Of these, k-means appears to
perform the best [7-9]. Relatedly, gene shaving [10]
searches for clusters of genes showing both high varia-
tion across the samples and correlation across the
genes, and several biclustering algorithms (such as [11])
search for class-conditional clusters of correlated genes.
These methods are simple, visually appealing, and have
identified a number of co-regulated genes and pheno-
type classes.
While these approaches have been fruitful, they also
have the potential to miss causative mechanisms that
can be deleteriously affected in several ways (such that
no particular alteration is dominant in the case samples)
as well as those which are only deleteriously affected
through a combination of particular alterations (such
that control samples may have some, but not all, the
alterations necessary to produce the case phenotype). It
is well known that complex diseases, such as cancers,
exhibit considerable molecular heterogeneity for these
reasons [12]. As a result, individual genes may fail to
reach significance, and lists of differentially expressed
genes or gene signatures may have poor concordance
across studies. Additionally, pathway analyses that rely
on single-gene association statistics (such as GSEA [2])
may fail to identify causative mechanisms. For the same
reasons, clustering algorithms that rely on linearly-
separable clusters (and hence upon differential expres-
sion between the clusters) may fail to partition the sam-
ples in a manner that reflects the true underlying
biology.
As an example of how causative genes can be missed
in gene-centric analyses, consider a recent study in
which gene expression profiles in the Wagyu cattle are
compared to those of the double-muscled Piedmontese
cattle [13]. The Piedmontese cattle’s muscular hypertro-
phy is attributable to a nonfunctional mutation of the
myostatin gene (MSTN), but because MSTN itself is not
differentially expressed between the two bovine models,
its biological role cannot be inferred using traditional
analyses of gene expression data. On the other hand,
[13] showed that the functional MSTN variant was co-
expressed with its regulatory target MYL2 in Wagyu
cattle, whereas the nonfunctional variant in the Pied-
montese cattle did not exhibit co-expression with
MYL2. The correct identification of this system, in the
absence of differential expression at the gene level in
MSTN or MYL2, is crucial to understanding the mole-
cular determinants of the double-muscled phenotype.
This example serves to underscore the pressing need for
analysis methods that can reveal systems-level differences
in cases and controls even when the constituent genes
do not exhibit differential expression.
As an alternative approach, we propose here an analy-
sis technique that is designed to reveal relationships
between samples based on multi-gene expression pro-
files without requiring that the genes be differentially
expressed (i.e., without requiring the samples to be line-
arly separable in the gene-expression space), and that
has the power to reveal relationships between samples
at various scales, permitting the identification of pheno-
typic subtypes. Our approach adapts a new unsupervised
machine-learning technique, the Partition Decoupling
Method (PDM) [14,15], to gene expression data. The
PDM consists of two iterated components: a spectral
clustering step, in which the correlations between sam-
ples in the high-dimensional feature space are used to
partition samples into clusters, followed by a scrubbing
step, in which a projection of the data onto the cluster
centroids is removed so that the residuals may be clus-
tered. As part of the spectral clustering procedure, a
low-dimensional nonlinear embedding of the data is
used; as we will show in the Methods section, this both
reduces the effect of noisy features and permits the par-
titioning of clusters with non-convex boundaries. The
clustering and scrubbing steps are iterated until the resi-
duals are indistinguishable from noise, as determined by
comparison to a resampled null model. This procedure
yields “layers” of clusters that articulate relationships
between samples at progressively finer scales, and distin-
guishes the PDM from other clustering algorithms.
The PDM has a number of satisfying features. The use
of spectral clustering allows identification of clusters
that are not necessarily separable by linear surfaces, per-
mitting the identification of complex relationships
between samples. This means that clusters of samples
can be identified even in situations where the genes do
n o te x h i b i td i f f e r e n t i a le x p r e s s i o n ,at r a i tt h a tm a k e si t
particularly well-suited to examining gene expression
profiles of complex diseases. The PDM employs a low-
dimensional embedding of the feature space, reducing
the effect of noise in microarray studies. Because the
data itself is used to determine both the optimal number
of clusters and the optimal dimensionality in which the
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entirely unsupervised method for classification without
relying upon heuristics. Importantly, the use of a
resampled null model to determine the optimal dimen-
sionality and number of clusters prevents clustering
when the geometric structure of the data is indistin-
g u i s h a b l ef r o mc h a n c e .B ys c r u b b i n gt h ed a t aa n d
repeating the clustering on the residuals, the PDM per-
mits the resolution of relationships between samples at
various scales; this is a particularly useful feature in the
context of gene-expression analysis, as it permits the
discovery of distinct sample subtypes. By applying the
PDM to gene subsets defined by common pathways, we
can use the PDM to identify gene subsets in which bio-
logically meaningful topological structures exist, and
infer that those pathways are related to the clinical char-
acteristics of the samples (that is, if the genes in a parti-
cular pathway admit unsupervised PDM partitioning
that corresponds to tumor/non-tumor cell types, one
may infer that pathway’s involvement in tumorigenesis).
This pathway-based approach has the benefit of incor-
porating existing knowledge and being interpretable
from a biological standpoint in a way that searching for
sets of highly significant but mechanistically unrelated
genes does not.
A number of other operationally similar, yet function-
ally distinct, methods have been considered in the litera-
ture. First, simple spectral clustering has been applied to
gene expression data in [9], with mixed success. The
PDM improves upon this both through the use of the
resampled null model to provide a data-driven (rather
than heuristic) choice of the clustering parameters, and
by its ability to articulate independent partitions of the
data (in contrast to a single layer) where such structure
is present. As we will show, these aspects make the
PDM more powerful than standard spectral clustering,
yielding improved accuracy as well as the potential to
identify sample subtypes that are not already known.
Another novel clustering method is proposed in [16],
w h e r ea na d a p t i v ed i s t a n c en o r mi su s e dt h a tc a nb e
shown to identify clusters of different shapes. The algo-
rithm iteratively assigns clusters and refines the distance
metric scaling parameter in a cluster-conditional fashion
based on each cluster’s geometry. This approach is able
to identify clusters of mixed sizes and shapes that can-
not be discriminated using fixed Euclidean or Mahala-
nobis distance metrics, and thus is a considerable
improvement over k-means clustering. However, the
method as described in [16] is computationally expen-
sive and cannot identify non-convex clusters as spectral
clustering, and hence the PDM, can.
Alternatively, SPACC [17] uses the same type of non-
linear embedding of the data as is used in the PDM,
which permits the articulation of non-convex
boundaries. In SPACC [17], a single dimension of this
embedding is used to recursively partition the data into
two clusters. The partitioning is carried out until each
cluster is solely comprised of one class of samples, yield-
ing a classification tree. In this way, SPACC may also in
some cases permit partitioning of known sample classes
into subcategories. However, SPACC differs from the
PDM in two crucial ways. First, the PDM’su s eo fa
data-determined number of informative dimensions per-
mits more accurate clusterings than those obtained
from a single dimension in SPACC. Second, SPACC is a
semi-supervised algorithm that uses the known class
labels to set a stopping threshold. Because there is no
comparison to a null model, as in the PDM, SPACC will
partition the data until the clusters are pure with respect
to the class labels. This means that groups of samples
with distinct molecular subtypes but identical class
labels will remain unpartitioned (SPACC may not reveal
novel subclasses) and that groups of samples with differ-
ing class labels but indistinguishable molecular charac-
teristics will be artificially divided until the purity
threshold is reached. By contrast, the clustering in the
PDM does not impose assumptions about the number
of classes or the relationship of the class labels to the
clusters in the molecular data.
A fourth approach, QUBIC [11] is a graph theoretic
algorithm that identifies sets of genes with similar class-
conditional coexpression patterns (biclusters) by
employing a network representation of the gene expres-
sion data and agglomeratively finding heavy subgraphs
of co-expressed genes. In contrast to the unsupervised
clustering of the PDM, QUBIC is a supervised method
that is designed to find gene subsets with coexpression
patterns that differ between pre-defined sample classes.
In [11] it is shown that QUBIC is able to identify func-
tionally related gene subsets with greater accuracy than
competing biclustering methods; still, QUBIC is only
able to identify biclusters in which the genes show strict
correlation or anticorrelation coexpression patterns,
which means that gene sets with more complex coex-
pression dynamics cannot be identified.
The PDM is thus unique in a number of ways: not
only is it able to partition clusters with nonlinear and
nonconvex boundaries, it does so in an unsupervised
manner (permitting the identification of unknown sub-
types) and in the context of comparison to a null distri-
bution that both prevents clustering by chance and
reduces the influence of noisy features. Moreover, the
PDM’s iterated clustering and scrubbing steps permit
the identification of independent (i.e., decoupled) parti-
tions in the data.
In this manuscript, we describe the PDM algorithm
and demonstrate its application to several publicly-avail-
able gene-expression data sets. To illustrate the PDM’s
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we apply it to genome-wide expression data from a four
phenotype, three exposure radiation response study [18].
The PDM partitions the samples by exposure and then
by phenotype, yielding higher accuracy for predictions
of radiation sensitivity than previously reported [18]. We
also compare the PDM results to those obtained in a
recent [9] comparison of clustering techniques, demon-
strating the PDM’s ability to identify cancer subtypes
from global patterns in the gene expression data. Next,
we apply the PDM using gene subsets defined by path-
ways rather than the global gene expression data,
demonstrating how the PDM can be used to find biolo-
gical mechanisms that relate to the phenotype of inter-
est. We demonstrate Pathway-PDM in both the
radiation response data [18] as well as a larger prostate
cancer data set [19]. Our results suggest that the PDM
is a powerful tool for articulating relationships between
samples and for identifying pathways containing multi-
gene expression patterns that distinguish phenotypes.
Results and Discussion
The Partition Decoupling Algorithm
The partition decoupling method (PDM) was first
described in [14]. We summarize it here, and discuss its
application to gene-expression data. The PDM consists
of two iterated submethods: the first, spectral clustering,
finds the dominant structures within the system, while
the second “scrubbing” step removes this structure such
that the next clustering iteration can distinguish finer-
scale relationships within the residual data. The two
steps are repeated until the residuals are indistinguish-
able from noise. By performing successive clustering
steps, factors contributing to the partitioning of the data
at different scales may be revealed.
Spectral Clustering
The first step, spectral clustering, serves to identify clus-
ters of samples in high-dimensional gene-expression
space. The motivation is simple: given a set of samples
and a measure of pairwise similarity sij between each
pair, we wish to partition data in such a way that the
samples within one cluster are significantly more similar
to each other than they are to the remainder of the
samples. A summary of the spectral clustering algorithm
is given in Table 1.
Spectral clustering offers several advantages over tradi-
tional clustering algorithms such as those reviewed in
[7]. Most importantly, no constraint is placed on the
geometry of the data, in contrast to the tree-like struc-
ture imposed by hierarchical clustering [3] or the neces-
sity of convexity of the clusters for detection via
distance-based k-means clustering as used in [4,5], and
in Self Organizing Maps [6]. Spectral clustering also
uses a low-dimensional embedding of the data, thus
excluding the noisy, high-frequency components.
In spectral clustering, the data are represented as a
complete graph in which nodes correspond to samples
and edge weights sij correspond to some measure of
similarity between a pair of nodes i and j. Spectral
graph theory (see, e.g., [20]) is brought to bear to find
groups of connected, high-weight edges that define
clusters of samples. This problem may be reformulated
as a form of the min-cut problem: cutting the graph
across edges with low weights, so as to generate sev-
eral subgraphs for which the similarity between nodes
is high and the cluster sizes preserve some form of bal-
ance in the network. It has been demonstrated [20-22]
that solutions to relaxations of these kinds of combina-
torial problems (i.e., converting the problem of finding
a minimal configuration over a very large collection of
discrete samples to achieving an approximation via the
solution to a related continuous problem) can be
framed as an eigendecomposition of a graph Laplacian
matrix L. The Laplacian is derived from the similarity
matrix S (with entries sij) and the diagonal degree
matrix D (where the ith element on the diagonal is the
degree of entity i, ∑j sij), normalized according to the
formula
L = L − D−1/2SD−1/2. (1)
In spectral clustering, the similarity measure sij is
computed from the pairwise distances rij between
Table 1 Procedure for Spectral Clustering.
Spectral Clustering Algorithm
1. Compute the correlation rij between all pairs of n data points i and j.
2. Form the similarity matrix S Î ℝ
n×n defined by sij = exp [- sin
2 (arccos(rij)/2)/s
2], where s is a scaling parameter (s = 1 in the reported results).
3. Define D to be the diagonal matrix whose (i,i) elements are the column sums of S.
4. Define the Laplacian L = I - D
-1/2SD
-1/2.
5. Find the eigenvectors {v0, v1, v2,...,vn-1} with corresponding eigenvalues 0 ≤ l1 ≤ l2 ≤ ... ≤ ln-1 of L.
6. Determine from the eigendecomposition the optimal dimensionality l and natural number of clusters k (see text).
7. Construct the embedded data by using the first l eigenvectors to provide coordinates for the data (i.e., sample i is assigned to the point in the
Laplacian eigenspace with coordinates given by the ith entries of each of the first l eigenvectors, similar to PCA).
8. Using k-means, cluster the l-dimensional embedded data into k clusters.
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model local neighborhoods,
sij = exp

−r2
ij
2σ2

, (2)
where scaling the parameter s controls the width of
the Gaussian neighborhood, i.e., the scale at which dis-
tances are deemed to be similar. (In our analysis, we use
s = 1, though it should be noted that how to optimally
choose s is an open question [21,22].) Following [15],
we use a correlation-based distance metric in which the
correlation rij between samples i and j is converted to a
chord distance on the unit sphere,
rij = 2sin(arccos(ρij)/2). (3)
The use of the signed correlation coefficient implies
that samples with strongly anticorrelated gene expres-
sion profiles will be dissimilar (small sij) and is moti-
vated by the desire to distinguish between samples that
positively activate a pathway from those that down-regu-
late it.
Eigendecomposition of the normalized Laplacian L
given in Eq. 1 yields a spectrum containing information
regarding the graph connectivity. Specifically, the num-
ber of zero eigenvalues corresponds to the number of
connected components. In the case of a single con-
nected component (as is the case for almost any correla-
tion network), the eigenvector for the second smallest
(and thus, first nonzero) eigenvalue (the normalized Fie-
dler value l1 and Fiedler vector v1)e n c o d e sac o a r s e
geometry of the data, in which the coordinates of the
normalized Fiedler vector provide a one-dimensional
embedding of the network. This is a “best” embedding
in the sense that it solves a relaxation of an optimization
problem that seeks to determine an optimal partitioning
of the data (see [20-22]). This one-dimensional summary
provides the greatest dimension reduction–but optimal
with respect to the dimensionality–of the data. Finer
resolution is provided by the dimension reductions
obtained by increasing the dimensionality via the use of
additional eigenvectors (in order, according to increasing
eigenvalue).
By embedding the data into a smaller-dimensional
space defined by the low-frequency eigenvectors and
clustering the embedded data using k-means [4], the
geometry of the data may be revealed. Because k-means
clustering is by nature stochastic [4], multiple k-means
runs are performed and the clustering yielding the smal-
lest within-cluster sum of squares is chosen. In order to
use k-means on the embedded data, two parameters
need to be chosen: the number of eigenvectors l to use
(that is, the dimensionality of the embedded data) and
the number of clusters k into which the data will be
clustered.
Optimization of l The optimal dimensionality of the
embedded data is obtained by comparing the eigenva-
lues of the Laplacian to the distribution of Fiedler values
expected from null data. The motivation of this
approach follows from the observation that the size of
eigenvalues corresponds to the degree of structure (see
[22]), with smaller eigenvalues corresponding to greater
structure. Specifically, we wish to construct a distribu-
tion of null Fiedler values–eigenvalues encoding the
coarsest geometry of randomly organized data–and
select the eigenvalues from the true data that are signifi-
cantly small with respect to this distribution (below the
0.05 quantile). In doing so, we select the eigenvalues
that indicate greater structure than would be expected
by chance alone. The idea is that the distribution of ran-
dom Fiedler values give a sense of how much structure
we could expect of a comparable random network. We
thus take a collection of perpendicular axes, onto each
of which the projection of the data would reveal more
structure than we would expect at random.
The null distribution of Fiedler values is obtained
through resampling sij (preserving sij = sji and sii =1 ) .
This process may be thought of as “rewiring” the net-
work while retaining the same distribution of edge
weights. This has the effect of destroying structure by
dispersing clusters (subgraphs containing high edge
weights) and creating new clusters by random chance.
Because the raw data itself is not resampled, the result-
ing resampled network is one which has the same mar-
ginal gene expression distributions and gene-gene
correlations as the original data, and is thus a biologi-
cally comparable network to that in the true data. Note
that the resampling-based (and hence nonparametric)
construction of the reference distribution here differs
from the previous description of the PDM [15] that
employed a Gaussian ensemble null model.
Eigenvectors whose eigenvalues are significantly small
with respect to the resampled null model are retained as
the coordinates that describe the geometry of the system
that distinguishable from noise, yielding a low-dimen-
sional embedding of the significant geometry. If none of
the eigenvalues are significant with respect to the
resampled null reference distribution, we conclude that
no coordinate encodes more significant cluster structure
than would be obtained by chance, and halt the process.
Optimization of k The development of methods for
obtaining the number of clusters k suitable for partition-
ing a data set is an area of active research (see, e.g.,
[22,23] and references therein). Our approach exploits
the property [15,22] that clustering the entries in the
Fiedler vector yields the best decomposition of the
Braun et al. BMC Bioinformatics 2011, 12:497
http://www.biomedcentral.com/1471-2105/12/497
Page 5 of 19network components. Consequently, one can use the
number peaks in the density of the Fiedler vector–that
is, the number of values about which the elements of v1
are clustered–as the number of clusters. (This procedure
is roughly analogous to finding regions of high density
along the first principle component of the data.) To
obtain this value, we fit a Gaussian mixture model [24]
with 2-30 components (assuming unequal variances),
compute the Bayesian Information Criterion (BIC) for
each mixture model, and choose the optimum number
of components (for details of the implementation, see
[25,26]).
Once k and l have been assigned, the data embedded
via the coordinates given by the eigenvectors of the
smallest l nonzero eigenvalues is clustered using k-
means [4]. The spectral clustering procedure offers sev-
eral advantages over simple clustering of the original
data using k-means: first, the Fiedler vector provides a
natural means to estimate the number of clusters; and
second, because spectral clustering operates on similar-
ity of the samples, rather than planar cuts of the high-
dimensional feature space, complex correlation struc-
tures can be identified. A complete discussion of the
advantages of spectral clustering is given in [20-22].
To illustrate the power of this method, consider a toy
data set called “two_circles” in which 200 data points
are placed in two-dimensional space in two concentric
circles, as depicted in Figure 1. Because k-means alone
can only identify clusters with convex hulls, k-means
clustering using k = 2 produces an arbitrary, linear divi-
sion of the data as shown in Figure 1(a). In contrast,
spectral clustering identifies the two rings as individual
clusters, as seen in Figure 1(b). While k-means took k =
2 as an input from the user, the spectral clustering
example determined k = 2 from the data, as shown in
Figure 1(c); the rug plot depicts the distribution of the
Fiedler vector coordinates, in which two peaks are read-
ily visible and chosen as indicative of two clusters, as
described above.
While the two_circles data is simulated, we note that
patterns of this type will arise when out-of-phase oscilla-
tory genes, such as those involved in circadian rhythms
or cell cycle processes, are sampled; the radii of the co-
expression circles will be dictated by the amplitude of
the gene oscillations. An illustration of such patterns in
nature is provided in Figure 2, which depicts the co-
expression pattern of three cell-cycle related genes in
CDC-28 and elutriation synchronized yeast cells from
[27]. The elutriation synchronized cells exhibit much
smaller amplitude oscillations than do the CDC-28 syn-
chronized cells; while the CDC-28 and elutriation syn-
chronized cells cannot be distinguished using k-means,
the distinction is readily made via spectral clustering.
The biological relevance of patterns such as those
Figure 1 two circles examples. In (a) and (b), colors denote cluster
assignments from k-means (k = 2) and spectral clustering,
respectively. In (a), k-means using k = 2 produces a linear cut
through the data; in (b), spectral clustering automatically chooses
two clusters and assigns clusters with nonconvex boundaries. The
spectrally embedded data used in (b) is shown in (c); in this
representation, the clusters are linearly separable, and a rug plot
shows the bimodal density of the Fiedler vector that yielded the
correct number of clusters.
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lian systems as well; in [28] it is found that the majority
of mammalian genes oscillate and that the amplitude of
oscillatory genes differs between tissue types and is
associated with the gene’s function. These observations
led to the conclusion in [28] that pathways should be
considered as dynamic systems of genes oscillating in
coordination with each other, and underscores the need
Figure 2 Yeast cell cycle data. Expression levels for three oscillatory genes are shown. The method of cell cycle synchronization is shown as
shapes: crosses denote elutriation-synchronized samples, while triangles denote CDC-28 synchronized samples. Cluster assignment for each
sample is shown by color; above the diagonal, points are colored by k-means clustering, with poor correspondence between cluster (color) and
synchronization protocol (shapes); below the diagonal, samples are colored by spectral clustering assignment, showing clusters that correspond
to the synchronization protocol.
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depicted in Figures 1 and 2.
The benefit of spectral clustering for pathway-based
analysis in comparison to over-representation analyses
such as GSEA [2] is also evident from the two_circles
example in Figure 1. Let us consider a situation in
which the x- a x i sr e p r e s e n t st h ee x pression level of one
gene, and the y-axis represents another; let us further
assume that the inner ring is known to correspond to
samples of one phenotype, and the outer ring to
another. A situation of this type may arise from differ-
ential misregulation of the x and y axis genes. However,
while the variance in the x-axis gene differs between the
“inner” and “outer” phenotype, the means are the same
(0 in this example); likewise for the y-axis gene. In the
typical single-gene t- t e s ta n a l y s i so ft h i se x a m p l ed a t a ,
we would conclude that neither the x-axis nor the y-axis
gene was differentially expressed; if our gene set con-
sisted of the x-axis and y-axis gene together, it would
not appear as significant in GSEA [2], which measures
an abundance of single-gene associations. Yet, unsuper-
vised spectral clustering of the data would produce cate-
gories that correlate exactly with the phenotype, and
from this we would conclude that a gene set consisting
of the x-axis and y-axis genes plays a role in the pheno-
types of interest. We exploit this property in applying
the PDM by pathway to discover gene sets that permit
the accurate classification of samples.
Scrubbing
After the clustering step has been performed and each
data point assigned to a cluster, we wish to “scrub out”
the portion of the data explained by those clusters and
consider the remaining variation. This is done by com-
puting first the cluster centroids (that is, the mean of all
the datapoints assigned to a given cluster), and then
subtracting the data’s projection onto each of the cen-
troids from the data itself, yielding the residuals. The
clustering step may then be repeated on the residual
data, revealing structure that may exist at multiple
levels, until either a) no eigenvalues of the Laplacian in
the scrubbed data are significant with resepct to those
obtained from the resampled graphs as described above;
or b) the cluster centroids are linearly dependent. (It
should be noted here that the residuals may still be
computed in the latter case, but it is unclear how to
interpret linearly dependent centroids.)
Application to Microarray Data
We apply the PDM to several cancer gene expression
data sets to demonstrate how it may be used to reveal
multiple layers of structure. In the first data set [18], the
PDM articulates two independent partitions correspond-
ing to cell type and cell exposure, respectively. Analysis
of the second data [9] set demonstrates how successive
partitioning by the PDM can reveal disease and tissue
subtypes in an unsupervised way. We then show how
the PDM can be used to identify the biological mechan-
isms that drive phenotype-associated partitions, an
approach that we call “Pathway-PDM.” In addition to
applying it to the radiation response data set mentioned
above [18], we also apply Pathway-PDM to a prostate
cancer data set [19], and briefly discuss how the Path-
way-PDM results show improved concordance of signifi-
cant pathways identified in the Singh data [19] with
those previously identified in several other prostate can-
cer data sets [29].
Partition Decoupling in Cancer Gene Expression Data
Radiation Response Data
We begin by applying the PDM to the radiation
response data [18] to illustrate how it may be used to
reveal multiple layers of structure that, in this case, cor-
respond to radiation exposure and sensitivity. In the
first layer, spectral clustering classifies the samples into
three groups that correspond precisely to the treatment
type. The number of clusters was obtained using the
BIC optimization method as described above. Resam-
pling of the correlation coefficients was used to deter-
mine the dimension of the embedding l using 60
permutations (increasing this further did not alter the
eigenvalues deemed significant); 30 k-means runs were
performed and the clustering yielding the smallest
within-cluster sum of squares was chosen. Classification
results are given in Table 2 and Figure 3(a). The unsu-
pervised algorithm correctly identifies that three clusters
are present in the data, and assigns samples to clusters
in a manner consistent with their exposure.
In order to compare the performance of spectral clus-
tering to that of k-means, we ran k-means on the origi-
nal data using k =3a n dk = 4, corresponding to the
number of treatment groups and number of cell type
groups respectively. As with the spectral clustering, 30
random k means starts were used, and the smallest
within-cluster sum of squares was chosen. The results,
given in Tables 3 and 4, show substantially noisier clas-
sification than the results obtained via spectral cluster-
ing. It should also be noted that the number of clusters
k used here was not derived from the characteristics of
the data, but rather is assigned in a supervised way
Table 2 Spectral clustering of expression data versus
exposure; exposure categories are reproduced exactly.
Cluster
123
Mock 57 0 0
IR 0 57 0
UV 0 0 57
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Page 8 of 19Figure 3 PDM results for radiation response data. In (a) and (b) we see scatter plots of each sample’s Fiedler vector value along with the
resulting clustering (indicated by color) for the first (a) and second (b) PDM layers. A Gaussian mixture fit to the density (left panel) of the
Fiedler vector is used to assess the number of clusters, and the resulting cluster assignment for each sample is indicated by color. Exposure is
indicated by shape ("M"-mock; “U"-UV; “I"-IR), with phenotypes (healthy, skin cancer, radiation insensitive, radiation sensitive) grouped together
along the x-axis. In (a), it can be seen that the cluster assignment correlates with exposure, while in (b), cluster assignment correlates with
radiation sensitivity. In (c), points are placed in the grid according to cluster assignment from layers 1 and 2 along the x and y axes; it can be
seen that the UV-and IR- exposed high-sensitivity samples differ both from the mock-exposed high-sensitivity samples as well as the UV- and IR-
exposed control samples.
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of categories (here, dictated by the study design). While
the pure k-means results are noisy, the k = 4 classifica-
tion yields a cluster that is dominated by the highly
radiation-sensitive cells (cluster 4, Table 4). Membership
in this cluster versus all others identifies highly radia-
tion-sensitive cells with 62% sensitivity and 96% specifi-
city; if we restrict the analysis to the clinically-relevant
comparison between the last two cell types–that is, cells
from cancer patients who show little to no radiation
sensitivity and those from cancer patients who show
high radiation sensitivity–the classification identifies
radiation-sensitive cells with 62% sensitivity and 82%
specificity.
T h er e s u l tf r o mt h ek =4k-means classification sug-
gest that there exist cell-type specific differences in gene
expression between the high radiation sensitivity cells
and the others. To investigate this, we perform the
“scrubbing” step of the PDM, taking only the residuals
of the data after projecting onto the clusters obtained in
the first pass. As in the first layer, we use the BIC opti-
mization method to determine the number of clusters k
and resampling of the correlations to determine the
dimension of the embedding l using 60 permutations.
The second layer of structure revealed by the PDM par-
titioned the high-sensitivity samples from the others
into two clusters. Classification results are given in
Table 5 and Figure 3(b), and it can be seen that the par-
titioning of the radiation-sensitive samples is highly
accurate (83% sensitivity and 91% specificity across all
samples).
Further PDM iterations resulted in residuals that were
indistinguishable from noise (see Methods); we thus
conclude that there are only two layers of structure pre-
sent in the data: the first corresponding to exposure,
and the second to radiation sensitivity. That is, there
exist patterns in the gene expression space that distin-
guish UV- and ionizing radiation exposed cells from
mock-treated cells (and from each other), and that there
exist further patterns that distinguish high-sensitivity
cells from the rest. Together, these independent
(decoupled) sets of clusters describe six categories, as
shown in Figure 3(c), wherein the second layer parti-
tions the radiation sensitive cells from the others in
each exposure-related partition. The fact that the mock-
exposure as well as the UV- and IR-exposure partitions
are further divided by radiation sensitivity in the second
layer suggests that there exist constitutive differences in
the radiation sensitive cells that distinguish them from
the other groups even in the absence of exposure.
Importantly, the data-driven methodology of the PDM
identifies only phenotypic clusters, corresponding to the
high-sensitivity cells and the three control groups com-
bined, without further subpartitioning the combined
controls. This suggests that the three control groups do
not exhibit significant differences in their global gene-
expression profiles.
I nt h eo r i g i n a la n a l y s i so ft h i sd a t a[ 1 8 ] ,t h ea u t h o r s
used a linear, supervised algorithm (SAM, a nearest
shrunken centroids classifier [30]) to develop a predictor
for the high-sensitivity samples. This approach obtained
64.2% sensitivity and 100% specificity [18], yielding a
clinically useful predictor. The PDM’su n s u p e r v i s e d
detection of the high sensitivity sample cluster suggests
that the accuracy in [18] was not a result of overfitting
to training data; moreover, the PDM’s ability to identify
those samples with higher sensitivity than in [18] indi-
cates that there exist patterns of gene expression distinct
to the radiation-sensitive patients which were not identi-
fied in the SAM analysis, but are detectable using the
PDM.
DeSouto Multi-study Benchmark Data
Having observed the PDM’s ability to decouple indepen-
dent partitions in the four-phenotype, three-exposure
radiation response data, we next consider the PDM’s
ability to articulate disease subtypes. Because cancers
can be molecularly heterogeneous, it is often important
to articulate differences between subtypes–a distinction
Table 3 k-means clustering of expression data versus
exposure using k =3 .
Cluster
123
Mock 36 15 6
IR 36 15 6
UV 3 14 40
Table 4 k-means clustering of expression data versus cell
type using k =4 .
Cluster
1234
Healthy 19 18 8 0
Skin cancer 8 23 14 0
Low radiation sensitivity 13 11 8 7
High radiation sensitivity 6 1 9 26
Table 5 Spectral clustering of exposure data with
exposure-correlated clusters scrubbed out, versus cell
type.
Cluster
12
Healthy 45 0
Skin cancer 45 0
Low radiation sensitivity 28 11
High radiation sensitivity 7 35
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caused by radiation exposure. Here, we apply the PDM
to the suite of 21 Affymetrix data sets previously consid-
ered in [9]. The use of these sets is motivated by their
diversity and by the ability to compare the PDM perfor-
mance to that of the methods reported in [9].
In [9], the authors applied several widely used cluster-
ing algorithms–spectral clustering, hierarchical cluster-
ing, k-means, finite mixture of Gaussians (FMG), and
shared nearest-neighbor clustering–to the data using
various linkage and distance metrics as available for
each. In [9], the number of clusters k was set manually,
ranging over (kc,
√
n),w h e r ekc is the known number of
sample classes and n is the number of samples; in the
spectral clustering implementation, l was set equal to
the value chosen for k. Note that the PDM differs in
several crucial ways from basic spectral clustering as
a p p l i e di n[ 9 ] .F i r s t ,t h ec h o i c e so fk and l in the PDM
are data-driven (thus allowing a priori values for k that
is smaller than kc, and as many dimensions l as are sig-
n i f i c a n tc o m p a r e dt ot h en u l lm o d e la sp r e v i o u s l y
described). Second, the successive partitioning carried
out in the PDM layers can disambiguate mixed clusters.
Notably, the PDM partitions are obtained without rely-
ing on prior knowledge of the number of clusters. This
is an important feature when the data may contain un-
identified disease subtypes.
To illustrate this, we focus on a handful of the bench-
mark data sets. (Full results are provided in Additional
Files 1 and 2.) The partitions are shown in Figure 4. In
Figure 4(a) and 4(b), PDM reveals a single layer of three
clusters in two versions of the Golub-1999 leukemia
data [31]. The two data sets as provided contained iden-
tical gene expression measurements and differed only in
the sample status labels, with Golub-1999-v1 only dis-
tinguishing AML from ALL, but Golub-1999-v2 further
distinguishing between B- and T-cell ALL. As can be
seen from Figure 4(a,b), the PDM articulates a single
layer of three clusters, based on the gene expression
data. In Figure 4(a) (Golub-1999-v1), we see that the
AML samples are segregated into cluster 1, while the
ALL samples are divided amongst clusters 2 and 3; that
is, the PDM partition indicates that there exists struc-
ture, distinct from noise (as defined through the
resampled null model), that distinguishes the ALL sam-
ples as two subtypes. If we repeat this analysis with
Golub-1999-v2, we obtain the partitions shown in Figure
4(b). Since the actual gene expression data is identical,
the PDM partitioning of samples is the same; however,
we now can see that the division of the ALL samples
between clusters 2 and 3 corresponds to the B- and T-
cell subtypes. One can readily find–particularly in the
context of cancers–situations in which unknown sample
subclasses exist that could be detected via PDM (as in
Figure 4(a)); at the same time, the PDM’s comparison to
the resampled null model prevents artificial partitions of
the data.
In Figures 4(c) and 4(d), we see how the first layer of
clustering is refined in the second layer; for example, in
Figure 4(c), the E2A-PBX1 and T-ALL leukemias are
distinguished in the first layer, while the second serves
to separate the MLL and majority of the TEL-AML sub-
types from the mixture of B-cell ALLs in the first cluster
of layer 1. As in Figures 4(a) and 4(b), the PDM identi-
fies clusters of subtypes that may not be known a priori
(cf. results for Yeoh-2002-v1 in Additional Files 1 and 2,
for which all the B-cell ALLs had the same class label
but were partitioned, as in Figure 4(c), by several sub-
types). In Figure 4(d), second layer cluster assignment in
Figure 4(d) distinguishes the ovarian (OV) and kidney
(KI) samples from the others in the mixed cluster 2 in
the first layer.
Results for the complete set of Affymetrix benchmark
data are given in Additional Files 1 and 2. A t-test com-
parison of adjusted Rand indices obtained from the
PDM suggests that it is comparable to those obtained
with the best method, FMG, in [9]. However, it is
important to note that this is achieved by the PDM in
an entirely unsupervised way (in contrast to the heuris-
tic approach used to select k and l in [9]). This is a con-
s i d e r a b l ea d v a n t a g e .W ea l s on o t et h a tt h eP D M
performance remained high regardless of the distance
metric used (cf. Fig. S-1 vs. Fig. S-2 in Additional Files 1
and 2), and we did not observe the large decrease in
accuracy noted by [9] when using a Euclidean metric in
spectral clustering. We attribute this largely to the afore-
mented improvements (multiple layers; data-driven k
and l parameterization) of the PDM over standard spec-
tral clustering.
Pathway-PDM Analysis
The above applications of the PDM illustrate its ability
to detect clusters of samples with common exposures
and phenotypes based on genome-wide expression pat-
terns, without advance knowledge of the number of
sample categories. However, it is often of greater inter-
est to identify a set of genes that govern the distinction
between samples. Pathway-based application of the
PDM permits this by systematically subsetting the genes
in known pathways (here, based on KEGG [32] annota-
tions), and partitioning the samples. Pathways yielding
cluster assignments that correspond to sample charac-
teristics can then be inferred to be associated with that
characteristic. We call this approach the “Pathway-
PDM.”
We applied Pathway-PDM as described above to the
radiation response data from [18], testing the clustering
results obtained for inhomogeneity with respect to the
Braun et al. BMC Bioinformatics 2011, 12:497
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Page 11 of 19Figure 4 PDM results for several benchmark data sets. Points are placed in the grid according to cluster assignment from layers 1 and 2 (in
(a) and (b) no second layer is present). In (a) and (b) it can be seen that the PDM identifies three clusters, and that the division of the ALL
samples in (a) corresponds to a subtype difference (ALL-B, ALL-T) shown in (b). In (c) and (d), it can be seen that the partitioning of samples in
the first layer is refined in the second PDM layer.
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2 test). Because some pathways contain a
fairly large number of probes, it is reasonable to ask
whether the pathways that permitted clusterings corre-
sponding to tumor status were simply sampling the
overall gene expression space. In order to assess this, we
also constructed artificial pathways of the same size as
each real pathway by randomly selecting the appropriate
number of probes, and recomputing the clustering and
c
2 p-value as described above. 1000 such random path-
ways were created for each unique pathway length, and
the fraction frand of pathways that yielded a c
2 p-value
smaller than that observed in the “true” pathway is used
as an additional measure of the pathway significance.
Six pathways distinguished the radiation-sensitive sam-
ples with frand <0.05 as shown in Figure 5; several also
articulated exposure-associated partitions in addition to
the phenotype-associated partition. Interestingly, all of
the high-scoring pathways separated the high-RS case
samples, but did not subdivide the three control sample
classes; this finding, as well as the exposure-independent
clustering assignments in several pathways in Figure 5,
suggests that there are systematic gene expression differ-
ences between the radiation-sensitive patients and all
others. Several other pathways (see Figure S-3 in Addi-
tional File 3) yield exposure-associated partitions with-
out distinguishing between phenotypes; unsurprisingly,
these are the cell cycle, p53 signaling, base excision
repair, purine metabolism, MAP kinase, and apoptosis
pathways.
To further illustrate Pathway-PDM, we apply it to the
Singh prostate gene expression data [19] (the heavily-fil-
tered sets from [9] have too few remaining probes to
meaningfully subset by pathway). First, we observe that
in the complete gene expression space, the clustering of
samples corresponds to the tumor status in the second
PDM layer (Figure S-4 in Additional File 4). This is con-
sistent with the molecular heterogeneity of prostate can-
cer, and suggests that the first layer describes individual
variation that is scrubbed out and then revealed in the
second layer. Next, we apply Pathway-PDM as described
above, testing each layer of clustering for inhomogeneity
with respect to the known tumor/normal labels (c
2 test).
Of the 203 pathways considered, those that yielded
significant frand in any layer of clustering is given in
Table 6. No pathway yielded more than two layers of
structure. A total of 29 of 203 pathways exhibited signif-
icant clustering inhomogeneity in any layer; amongst the
significant pathways, the misclassification rate–the frac-
tion of tumor samples that are placed in a cluster that is
majority non-tumor and vice-versa–is approximately
20%. Plots of the six most discriminative pathways in
layers 1 and 2 are given in Figure 6.
A number of known prostate cancer-related pathways
appear at the top of this list. The urea acid cycle
pathway, prion disease pathway, and bile acid synthesis
pathways have previously been noted in relationship to
prostate cancer [29]. The coagulation cascade is known
to be involved in tumorigenesis through its role in
angiogenesis [33], and portions of this pathway have
been implicated in prostate metastasis [34]. Cytochrome
P450, which is part of the inflammatory response, has
been implicated in many cancers [35], including prostate
[36], with the additional finding that it may play a role
in estrogen metabolism (critical to certain prostate can-
cers) [37]. Many amino acid metabolism pathways (a
hallmark of proliferating cells) and known cancer-asso-
ciated signaling pathways (Jak-STAT, Wnt) are also
identified.
Because Pathway-PDM does not rely upon single-gene
associations and employs a “scrubbing” step to reveal
progressively finer relationships, we expect that we will
be able to identify pathways missed by other methods. It
is of interest to compare the results obtained by Path-
way-PDM to those obtained by other pathway analysis
techniques. In [29], the authors applied several estab-
lished pathway analyses (Fisher’s test, GSEA, and the
Global Test) to a suite of three prostate cancer gene
expression data sets, including the Singh data consid-
ered here. Fifty-five KEGG pathways were identified in
a tl e a s to n ed a t as e tb ya tl e a s to n em e t h o d[ 2 9 ] ,b u t
with poor concordance: 15 of these were found solely in
the Singh data, and 13 were found in both the Singh
data and at least one of the other two data sets (Welsh
[38], Ernst [39]) using any method. A comparison of the
Pathway-PDM identified pathways to those reported in
[29] is given by the final column of Table 6, which lists
the data sets for which that pathway was found to be
significant using at least one method (Fisher’st e s t ,
GSEA, and the Global Test) reported in [29]. Of the 29
Pathway-PDM identified pathways, 16 had been identi-
fied by [29] in either the Welsh or Ernst data (including
7 found by other methods in the Singh data by [29]).
The PDM-identified pathways show improved concor-
dance with the pathways identified in [29]; while only
13 of the 40 pathways identified in the Welsh or Ernst
data were corroborated by the Singh data using any
method in [29], the addition of the Pathway-PDM Singh
r e s u l t sb r i n g st h i st o2 2 / 4 0 .O ft h e1 3p a t h w a y sn e w l y
introduced in Table 6, several are already known to play
ar o l ei np r o s t a t ec a n c e rb u tw e r en o td e t e c t e du s i n g
the methods in [29] (such as cytochrome P450, comple-
ment and coagulation cascades, and Jak-STAT signal-
ling); several also constitute entries in KEGG that were
either not present at the time that [29] was published or
have had over 30% of genes added/removed, making
them incomparable to the KEGG annotations used in
[29]. This improved concordance supports the inferred
role of the PDM-identified pathways in prostate cancer,
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way-PDM is able to detect pathway-based gene expres-
sion patterns missed by other methods.
Conclusions
We have presented here a new application of the Parti-
tion Decoupling Method [14,15] to gene expression pro-
filing data, demonstrating how it can be used to identify
multi-scale relationships amongst samples using both
the entire gene expression profiles and biologically-rele-
vant gene subsets (pathways). By comparing the unsu-
pervised groupings of samples to their phenotype, we
use the PDM to infer pathways that play a role in
disease.
The PDM has a number of features that make it pre-
ferable to existing microarray analysis techniques. First,
the use of spectral clustering allows identification of
clusters that are not necessarily separable by linear sur-
faces, enabling the identification of complex relation-
ships between samples. As this relates to microarray
data, this corresponds to the ability to identify clusters
of samples even in situations where the genes do not
exhibit differential expression. This is particularly useful
when examining gene expression profiles of complex
diseases, where single-gene etiologies are rare. We
observe the benefit of this feature in the example of Fig-
ure 2, where the two separate yeast cell groups could
not be separated using k-means clustering but could be
correctly clustered using spectral clustering. We note
that, like the genes in Figure 2, the oscillatory nature of
many genes [28] makes detecting such patterns crucial.
Second, the PDM employs not only a low-dimensional
embedding of the feature space, thus reducing noise (an
important consideration when dealing with noisy
Figure 5 Pathway-PDM results for top pathways in radiation response data. Points are placed in the grid according to cluster assignment
from layers 1 and 2 along for pathways with frand <0.05. Exposure is indicated by shape ("M"-mock; “U"-UV; “I"-IR), with phenotypes (healthy, skin
cancer, low RS, high RS) indicated by color. Several pathways (nucleotide excision repair, Parkinson’s disease, and DNA replication) cluster
samples by exposure in one layer and phenotype in the other, suggesting that these mechanisms differ between the case and control groups.
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and number of clusters is data-driven rather than heur-
istically set. This makes the PDM an entirely unsuper-
vised method. Because those parameters are obtained
with reference to a resampled null model, the PDM pre-
vents samples from being clustered when the relation-
ships amongst them are indistinguishable from noise.
We observed the benefit of this feature in the radiation
response data [18] shown in Figure 3, where two (as
opposed to four) phenotype-related clusters were articu-
lated by the PDM: the first corresponding to the high-
RS cases, and the second corresponding to a combina-
tion of the three control groups.
Third, the independent “layers” of clusters (decoupled
partitions) obtained in the PDM provide a natural
means of teasing out variation due to experimental
conditions, phenotypes, molecular subtypes, and non-
clinically relevant heterogeneity. We observed this in the
r a d i a t i o nr e s p o n s ed a t a[ 1 8 ] ,w h e r et h eP D Mi d e n t i f i e d
the exposure groups with 100% accuracy in the first
layer (Figure 3 and Table 2) followed by highly accurate
classification of the high-RS samples in the second layer
(Figure 3 and Table 5). The improved sensitivity to clas-
sify high-RS samples over linear methods (83% vs. the
64% reported using SAM in [18]) suggests that there
may exist strong patterns, previously undetected, of
gene expression that correlate with radiation exposure
and cell type. This was also observed in the benchmark
data sets [9], shown in Figure 4 and supplementary Figs.
S-1, S-2 (Additional Files 1 and 2), where the PDM
automatically detected subtypes in an unsupervised
manner without forcing the cluster number. The results
Table 6 Pathways with cluster assignment articulating tumor versus normal status in at least one PDM layer for the
Singh prostate data.
Layer 1 Layer 2
KEGG Pathway Lp p (c
2) frand p (c
2) frand In [29] ?
00220 Urea cycle & metabolism of amino groups 33 1.14e-13 <0.001 7.10e-01 0.940 [19,38,39]
00980 Metab. of xenobiotics by cytochrome P450 72 3.97e-13 0.001 –
00640 Propanoate metabolism 31 7.78e-12 0.003 9.78e-01 0.995 [38,39]
04610 Complement and coagulation cascades 75 9.21e-12 0.008 2.47e-02 0.371
00120 Bile acid biosynthesis 32 1.29e-01 0.699 1.15e-11 0.003 [19,38]
05060 Prion disease 18 5.18e-02 0.527 2.20e-11 0.003 [19,38,39]
00380 Tryptophan metabolism 50 3.84e-11 0.008 5.52e-01 0.894 [39]
00480 Glutathione metabolism 48 4.80e-11 0.008 8.37e-01 0.955 [19,38,39]
04310 Wnt signaling pathway 191 5.38e-11 0.017 5.47e-01 0.916 [38]
00983 Drug metabolism - other enzymes 52 5.08e-10 0.024 8.60e-01 0.966 –
04630 Jak-STAT signaling pathway 205 1.65e-01 0.826 8.41e-10 0.025
00053 Ascorbate and aldarate metabolism 8 3.32e-02 0.462 7.67e-09 0.008 [39]
00350 Tyrosine metabolism 45 1.32e-02 0.359 2.80e-08 0.040 [19,38]
00641 3-Chloroacrylic acid degradation 16 5.23e-08 0.016 6.89e-01 0.893
00960 Alkaloid biosynthesis II 8 7.13e-02 0.558 8.23e-08 0.016 [19]
00410 beta-Alanine metabolism 25 9.24e-08 0.016 1.60e-01 0.673 [39]
00650 Butanoate metabolism 37 9.39e-02 0.645 1.50e-07 0.014
00260 Glycine, serine & threonine metabolism 36 9.56e-02 0.645 1.78e-07 0.014 [38,39]
00600 Glycosphingolipid metabolism 32 7.84e-02 0.615 3.08e-07 0.016 [19]
00030 Pentose phosphate pathway 21 3.59e-07 0.022 2.80e-01 0.755 [38,39]
00062 Fatty acid elongation in mitochondria 11 1.68e-01 0.684 3.67e-07 0.022 [19,38]
00272 Cysteine metabolism 10 6.01e-07 0.025 7.52e-02 0.574 –
00340 Histidine metabolism 27 3.94e-02 0.477 1.42e-06 0.022 [39]
00720 Reductive carboxylate cycle 9 7.62e-02 0.574 1.51e-06 0.025 [19]
00565 Ether lipid metabolism 23 4.07e-06 0.036 8.43e-01 0.948 –
01032 Glycan structures - degradation 39 8.17e-01 0.957 4.62e-06 0.038
00360 Phenylalanine metabolism 19 2.32e-02 0.376 6.26e-06 0.044 [38,39]
00040 Pentose and glucuronate interconversions 17 7.75e-06 0.047 4.98e-01 0.843 [19]
00051 Fructose and mannose metabolism 35 4.49e-03 0.211 7.99e-06 0.043 [19,38]
The Lp column lists the size of the pathway. c
2 test p-values for tumor status versus cluster assignment in PDM layer 1 and layer 2 are given. The frand columns
show the fraction of randomly-generated pathways with smaller c
2 p-values in either PDM layer. The final column lists the data sets for which [29] identified the
pathway as significant ([19], Singh; [38], Welsh; [39], Ernst; a dash indicates pathways with significant revisions (>30% of genes added or removed) in KEGG
between this analysis and the time of [29] publication).
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benchmark data sets were at least as and generally more
accurate than those reported using other algorithms in
[9,18], were obtained without assumptions regarding the
sample classes, and reflect statistically significant (with
reference to the resampled null model) relationships
between samples in the data.
The accuracy of the PDM can be used, in the context
of gene subsets defined by pathways, to identify
mechanisms that permit the partitioning of phenotypes.
In Pathway-PDM, we subset the genes by pathway,
apply the PDM, and then test whether the PDM cluster
assignments reflect the known sample classes. Pathways
that permit accurate partitioning by sample class contain
genes with expression patterns that distinguish the
classes, and may be inferred to play a role in the biologi-
cal characteristics that distinguish the classes. This is a
novel approach to pathway analysis that improves upon
enrichment approaches in that does not require that the
pathway’s constituent genes be differentially expressed.
That is, we expect that Pathway-PDM will identify both
the pathways that would be identified in enrichment
analyses (since differentially expressed genes imply lin-
ear cluster boundaries) as well as those whose constitu-
ent genes would not yield high measures of differential
expression (such as in the two_circles example or the
Figure 6 Pathway-PDM results for the six most discriminative pathways in the Singh prostate data. Points are placed in the grid
according to cluster assignment from layers 1 and 2.
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Page 16 of 19yeast cell-cycle genes). This makes Pathway-PDM a pro-
mising tool for identifying mechanisms that show sys-
tems-level differences in their regulation that could be
missed by methods that rely on single-gene association
statistics.
To illustrate Pathway-PDM, we applied the Pathway-
PDM to both the radiation response data [18] and a
prostate cancer data set [19]. In the radiation response
data [18], we identified pathways that partitioned the
samples by phenotype and both by phenotype and expo-
sure (Figure 5) as well as pathways that only partitioned
the samples by exposure without distinguishing the phe-
notypes (Figure S-3 in Additional File 3). In the prostate
cancer data [19], we identified 29 pathways that parti-
tioned the samples by tumor/normal status (Table 6).
Of these, 15 revealed the significant tumor/normal parti-
tion in the second layer rather than the first (as did the
full-genome PDM–see Figure S-4 in Additional File 4),
and 13 of the 14 pathways with significant tumor/nor-
mal partitions in the first layer contained additional
structure in the second. Prostate cancer is known to be
molecularly diverse [19], and these partitions may reflect
unidentified subcategories of cancer or some other het-
erogeneity amongst the patients. By applying the Path-
way-PDM to the Singh data, we were able to improve
upon the pathway-level concordance reported in [29],
which applied pathway enrichment analyses (including
GSEA) to data from the Singh, Welsh, and Ernst pros-
tate cancer studies. We find not only that Pathway-
PDM identifies pathways in the Singh prostate data that
were identified in [29], but in addition identifies several
other pathways from the Singh data that were reported
by [29] in the Welsh and Ernst data, but not in the
Singh data. That is, despite the fact that these pathways
were not identified in the Singh data using GSEA, there
do exist patterns of gene expression that are detected by
Pathway-PDM; their identification in the other two data
sets corroborates their relevance and supports their
further investigation.
While our application of Pathway-PDM was such that
the clusters found by the PDM for each pathway were
compared against known sample class labels, we can
just as easily compare them to labels from the cluster
assignment from full-genome PDM. Hence, for example,
in a situation such as the Golub-1999-v1 data shown in
F i g u r e4 ( a ) ,w ec o u l du s et h e3 - c l u s t e ra s s i g n m e n t ,
rather than the 2-class sample labels, to find the path-
ways that permit the separation of cluster-2 ALLs from
the cluster-3 ALLs. In a case like this, where full-gen-
ome PDM analysis suggests the existence of disease sub-
types, applying Pathway-PDM may help identify the
molecular mechanisms that distinguish those samples.
(Note that the use of the PDM’s resampled null model
implies that such phenotype subdivisions are statistically
significant, rather than the result of an arbitrary cut of a
dendrogram.) Such an analysis would enable a refined
understanding of the molecular differences between the
subtypes and suggest alternative mechanisms to investi-
gate for diagnostic and therapeutic potential.
Despite these benefits, the PDM as applied here has
two potential drawbacks. First, while we obtained accu-
rate results from the PDM when setting s =1 ,t h e
dependence upon this scaling parameter in Eq. 1 is a
known issue in kernel-based methods, including spectral
clustering and KPCA [21,22]. Methods to optimally
select s are actively being developed, and several adap-
tive procedures have been suggested (eg, [40]) that may
allow for refined tuning of s. Second, the low-dimen-
sional nonlinear embedding of the data that makes spec-
tral clustering and the PDM powerful also complicates
the biological interpretation of the findings (in much the
same way that clustering in principal component space
might). Pathway-PDM serves to address this issue by
leveraging expert knowledge to identify mechanisms
associated with the phenotypes. Additionally, the nature
of the embedding, which relies upon the geometric
structure of all the samples, makes the classification of a
new sample challenging. These issues might be
addressed in several ways: experimentally, by investiga-
tion of the Pathway-PDM identified pathways (possibly
after further subsetting the genes to subsets of the path-
way) to yield a better biological understanding of the
dynamics of the system that were “snapshot” in the gene
expression data; statistically, by modeling the pathway
genes using an approach such as [41] that explicitly
accounts for oscillatory patterns (as seen in Figure 2) or
such as [13] that accounts for the interaction structure
of the pathway; or geometrically, by implementing an
out-of-sample extension for the embedding as described
in [42,43] that would allow a new sample to be classified
against the PDM results of the known samples.
In sum, our findings illustrate the utility of the PDM
in gene expression analysis and establish a new techni-
que for pathway-based analysis of gene expression data
that is able to articulate phenotype distinctions that
arise from systems-level (rather than single-gene) differ-
ences. We expect this approach to be of use in future
analysis of microarray data as a complement to existing
techniques.
Methods
Implementation and Availability
The PDM as described above was implemented in R
[44] and applied to the data sets below. Genes with
missing expression values were excluded when comput-
ing the (Pearson) correlation rij between samples. In the
l-optimization step, 60 resamplings of the correlation
coefficients were used to determine the dimension of
Braun et al. BMC Bioinformatics 2011, 12:497
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were performed, choosing the clustering yielding the
smallest within-cluster sum of squares. An free, open-
source R package to carry out the PDM is available for
download from http://braun.tx0.org/PDM.
Data
Radiation Response Data
These data come from a gene-expression profiling study
of radiation toxicity designed to identify the determi-
nants of adverse reaction to radiation therapy [18]. In
this study, skin fibroblasts from 14 patients with high
radiation sensitivity (High-RS) were collected and cul-
tured, along with those from three control groups: 13
patients with low radiation-sensitivity (Low-RS), 15
healthy individuals, and 15 individuals with skin cancer.
The cells were then subject to mock (M), ultraviolet (U)
and ionizing (I) radiation exposures. As reported in [18],
RNA from these 171 samples comprising four pheno-
types and three treatments were hybridized to Affyme-
trix HGU95AV2 chips, providing gene expression data
for each sample for 12615 unique probes. The microar-
ray data was normalized using RMA [45]. The gene
expression data is publicly available and was retrieved
from the Gene Expression Omnibus [46] repository
under record number GDS968.
DeSouto Multi-study Benchmark Data
These data comprise filtered gene expression levels from
21 cancer studies using Affymetrix microarrays along
with associated class labels. The data were analyzed pre-
viously in [9], where several clustering methods were
applied to compare algorithmic performance. The data
were obtained from their original sources and subjected
to filtering as described in [9]; we obtained the filtered
sets as used in [9] and made available by the authors.
This permits a direct comparison of the PDM results to
those reported in [9].
Singh Prostate Data
These data come from a gene-expression profiling study
of prostate cancer comprising 52 tumor samples (T) and
50 tumor-adjacent normal samples (N) from 52 men
who had undergone radical prostatectomy [19]. RNA
was hybridized to Affymetrix HGU95AV2 chips, provid-
ing gene expression data for each sample for 12615
u n i q u ep r o b e s .T h em i c r o a r r a yd a t aC E Lf i l e sw e r e
downloaded from the Broad Institute website and nor-
malized using RMA [45].
Pathway annotation
The BioConductor [47] annotation packages hgu95av2.
db, hgu95a.db, and KEGG.db were used to map Affyme-
trix probe IDs to KEGG pathways. Only KEGG path-
ways were investigated. A total of 203 KEGG pathways
containing genes probed in the above data were
identified.
Additional material
Additional File 1: Figure S-1. PDM classifications of deSouto benchmark
set samples using a correlation-based distance metric (as described in
methods).
Additional File 2: Figure S-2. PDM classifications of deSouto benchmark
set samples using a Euclidean distance metric.
Additional File 3: Figure S-3. Pathway-PDM classifications of radiation
response data for pathways that discriminate cells by radiation exposure
but not by phenotype, suggesting that these mechanisms are intact
across sample types. Exposure is indicated by shape ("M”, mock; “U”, UV;
“I”, IR), with phenotypes (healthy, skin cancer, low RS, high RS) indicated
by color. The discriminatory pathways relate to DNA metabolism and cell
death, as would be expected from radiation exposure.
Additional File 4: Figure S-4. PDM results in first and second layers of
the Singh prostate tumor data using all genes. The top two panels show
the Fiedler vector values and clustering results, along with the Fiedler
vector density, in the first and second layer; the bottom panel shows the
combined classification results. The second layer, but not the first,
discriminates the tumor samples.
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